SCHEMBL985865

SCHEMBL985865

Fc1c(Cl)cccc1-n1ccnc1-c1cc(Br)cnc1Cl

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.36
IDO1 P14902 1/20 0.33
KAT2B Q92831 1/20 0.33
MC4R P32245 6/20 0.33
MDM2 Q00987 2/20 0.33
NOTUM Q6P988 1/20 0.33
RXRA P19793 4/20 0.32
GRIN1 Q05586 4/20 0.32
GRIN2B Q13224 4/20 0.32
PDE4B Q07343 1/20 0.30
PDE4D Q08499 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984243 0.91 HCAR1 (0.33) HCAR1RXRAGRIN1GRIN2BGABRG2
SCHEMBL984877 0.88 HCAR1 (0.34) HCAR1MC4RGABRG2GABRB3GABRA5
SCHEMBL987103 0.76 P2RX7 (0.42)
SCHEMBL985336 0.71 HCAR1 (0.37) HCAR1IDO1KAT2BNOTUMRXRA
SCHEMBL982287 0.68 GABRA1 (0.38) NOTUMRXRAGRIN1GRIN2BGABRA5
SCHEMBL985584 0.67 USP7 (0.36) HCAR1MDM2NOTUMRXRAGRIN1
SCHEMBL986016 0.67 KCNN4 (0.46) RXRAGRIN1GRIN2B
SCHEMBL4406181 0.63 MAP4K4 (0.48)
SCHEMBL13073299 0.61 IDO1 (0.46) HCAR1IDO1GABRG2GABRB3GABRA5
SCHEMBL4406500 0.60 MAP4K4 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101479255-B C-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA 2013-05-01 CN disclosed
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
CN-101479255-A c-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA (US) 2009-07-08 CN disclosed
EP-2004625-A2 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Vertex Pharmaceuticals Incorporated (US) 2008-12-24 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed
WO-2007111904-A2 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 HCAR1 4131/4885IDO1 4573/4885KAT2B 3715/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 HCAR1 4131/4885IDO1 4573/4885KAT2B 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.